Moderna to Uncle Sam: My vaccine, not yours
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Friday
February 03, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
FRIDAY, FEBRUARY 03, 2023
Moderna to Uncle Sam: My vaccine, not yours

Panorama

Timothy L. O'Brien, Bloomberg
14 November, 2021, 02:10 pm
Last modified: 14 November, 2021, 02:12 pm

Related News

  • Rally, scientific seminar to prevent cervical cancer held at Labaid Hospital
  • Updated Covid vaccines prevented illness from latest variants -CDC
  • Vaccine misinformation spawns 'pure blood' movement
  • World renowned Vaccinologist Professor Dame Sarah Gilbert visits Incepta Pharma
  • Cancer vaccine hunt makes progress, finally

Moderna to Uncle Sam: My vaccine, not yours

The Covid-19 slayer is currently locked in a patent battle with the US government — its indispensable partner in the vaccine quest — that makes it look like just another pharmaceutical bully

Timothy L. O'Brien, Bloomberg
14 November, 2021, 02:10 pm
Last modified: 14 November, 2021, 02:12 pm
Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters
Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters

Moderna Inc. has been a marvel of the pandemic, a startup powered by science, private and public funding and smart people that produced a Covid-19 vaccine in record time. It helped save lives and shortened the course of an epic public health crisis.

Along the way, the company and its investors have also reaped vast financial rewards. Its share price has soared 116 percent over the past year and more than 650 percent since March 2, 2020, just before pandemic lockdowns began in earnest. 

Its market valuation over that latter stretch has grown from $9.8 billion to about $91.7 billion. It posted earnings of $3.3 billion on revenue of $5 billion in the third quarter, compared with a loss of $234 million against revenue of $158 million in the same period a year ago. The company recently said it has signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world.

So why is Moderna, with its reputation burnished and its coffers full, being so greedy?

The Covid-19 slayer is currently locked in a patent battle with the US government — its indispensable partner in the vaccine quest — that makes it look like just another pharmaceutical bully: grasping, tone deaf, financially insatiable and conveniently forgetful about some of the reasons behind its success.

Covid-19 Booster

Moderna collaborated with the National Institutes of Health and its scientists for four years to develop its vaccine, and the US government gave the company $10 billion in research and development money to pave the way. The government also agreed to purchase 500 million doses of Moderna's vaccine, guaranteeing a buyer from the get-go — and eliminating some of the market risk that can challenge drug companies.

Some of Moderna's funding was channelled through Operation Warp Speed, the government's all-hands-on-deck push that expedited deliveries of vaccines from several drug companies. But taxpayers had been subsidising Moderna's vaccine research since long before Operation Warp Speed emerged — leading analysts to speculate about whether the government was entitled to an ownership stake in the vaccine's intellectual property rights.

Although Moderna's vaccine most likely would not have existed without government support, the company filed a claim over the summer with the US Patent and Trademark Office asserting that its scientists alone designed a key genetic sequence that makes the vaccine so effective. The government strongly disagrees, saying three of its own scientists were central to that effort. 

Both parties tried to settle their disagreement behind the scenes, but this week the dispute spilt onto the pages of the New York Times. A court battle may be coming.

Moderna says it is willing to acknowledge the NIH and a trio of its researchers as "collaborators" but not as "co-inventors." The NIH says that such an omission "deprives NIH of a co-ownership interest in that application and the patent that will eventually issue from it." 

More than rights and profits stemming from a patent claim are at stake here. Having a rightful claim to a game-changing invention and a place in the history books matters, too. Barney Graham, an NIH scientist involved in the vaccine research, told the Times that the government's collaboration with Moderna went like this: "We did the front end. They did the middle. And we did the back end."

Others concur with that take. Earlier this week, Celine Gounder, an infectious disease specialist and New York University professor who was a member of the White House's Covid-19 Advisory Board, took to Twitter to criticise the company. "Moderna is cheating US taxpayers. Moderna is being scientifically dishonest. Moderna is trying to cheat NIH scientists," she wrote. 

"Meanwhile, many around the world still have not received a single dose of COVID vaccine."

Playing fast and loose with pricing, costs, transparency and proper credit for public partnerships is old hat for drug companies, unfortunately. Pharma has spent years saying hefty prices compensate it for hefty costs, which it has traditionally identified as all of the research and development spendings it incurs as part of inventing and producing blockbuster drugs. 

But the industry has never fully accounted for its costs, and some critics have pointed out that as much as a fifth of drug research is typically subsidised by the government. The drug companies also often enjoy monopoly pricing, and they have routinely deployed patent law warfare to stave off competitors.

To be sure, Moderna is in a tough industry contending with unusually challenging headwinds. Its stock got dinged last week after it disclosed that sales for the year would be billions of dollars lower than expected. It also missed earnings expectations. 

The company attributed the shortfalls to the difficulties associated with selling into an international market and supply chain headaches. It appears to be falling behind such competitors as Pfizer Inc. and BioNTech Se.

Yet Moderna remains financially flush, and the federal government helped get it here. 

Why is the company being so greedy? Maybe simply because it can. The government should not let it get away with this.


Timothy L O'Brien is a senior columnist for Bloomberg Opinion.


Disclaimer: This article first appeared on Bloomberg, and is published by special syndication arrangement.

 

Top News

Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Gautam Adani. Photo: Bloomberg
    Adani’s $108 billion crisis shakes investors’ faith in India
  • International Monetary Fund logo : AP via UNB
    IMF sets time-bound reform agenda as it releases first tranche of loan
  • Shipped Bhola gas to cost higher, yet cheaper than spot LNG
    Shipped Bhola gas to cost higher, yet cheaper than spot LNG

MOST VIEWED

  • The trio spearheading the revival of book cover designs
    The trio spearheading the revival of book cover designs
  • Andy Mukherjee. Sketch: TBS
    What makes India's billionaires' support special for Adani
  • While the Padma bridge in operation is changing the lives of millions in the south for the better, passenger rush to Shimulia ghat died down. Photo: Masum Billah
    How are the Shimulia ghat businesses faring after Padma bridge?
  • After so many investments going embarrassingly wrong, as was the case with Sam Bankman-Fried, perhaps tech investors’ preference for less experience will wane. Photo: Bloomberg
    Are you the next Steve Jobs? Good luck raising money in 2023
  • Infographic: TBS
    How to redirect inward remittances to formal channels
  • An elderly couple's lonely battle to save Dhaka's trees
    An elderly couple's lonely battle to save Dhaka's trees

Related News

  • Rally, scientific seminar to prevent cervical cancer held at Labaid Hospital
  • Updated Covid vaccines prevented illness from latest variants -CDC
  • Vaccine misinformation spawns 'pure blood' movement
  • World renowned Vaccinologist Professor Dame Sarah Gilbert visits Incepta Pharma
  • Cancer vaccine hunt makes progress, finally

Features

Andy Mukherjee. Sketch: TBS

What makes India's billionaires' support special for Adani

2h | Panorama
Photo: Rejaul Hafiz Rahi

A jackal farewell

3h | Earth
The trio spearheading the revival of book cover designs

The trio spearheading the revival of book cover designs

4h | Panorama
Six Jeep Wranglers and a special XJ Jeep Cherokee set out into the depths of Lalakhal, Sylhet for an experience of a lifetime. Photo: Ahbaar Mohammad

Jeep Life Bangladesh: A club for Jeep owners to harness the power of their vehicles

1d | Wheels

More Videos from TBS

A proper price formula can help investors to plan big

A proper price formula can help investors to plan big

18h | TBS Round Table
Rumors about Sarika that everyone thinks are true

Rumors about Sarika that everyone thinks are true

17h | TBS Entertainment
Mugging rife in Tejgaon, murder in Wari

Mugging rife in Tejgaon, murder in Wari

19h | TBS Current Affairs
What secrets are hidden behind Adani's wealth?

What secrets are hidden behind Adani's wealth?

18h | TBS Stories

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

3
Photo: Collected
Energy

8 Ctg power plants out of production

4
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

5
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

6
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]